46 results on '"Sternberg C"'
Search Results
2. 1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)
3. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
4. LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
5. 1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
6. P12.02 Implementation of a Timeliness-of-care Pathway System for Lung Cancer Patients in a Private Outpatient Oncology Service.
7. Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial
8. Association entre la qualité de vie liée à la santé (qdv) et les signes cliniques du cancer de prostate résistant à la castration non métastatique (cprcnm) : résultats de l’étude prosper
9. REASSURE observational study of radium-223 (Ra-223): First interim results by prior/concomitant treatment (Tx) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) enrolled in Europe
10. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet
11. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study
12. A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)
13. Prognostic impact of primary tumor location in advanced urothelial tract cancer (UCC); a pooled analysis of EORTC 30924, 30986, and 30987 trials
14. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study
15. TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
16. Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)
17. CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
18. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo
19. 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
20. 131. Progressing multi-modal therapies of pancreatic cancer by rational-based drug targeting of the oncogenic Hedgehog/GLI signaling network
21. P057 PROSPER: A phase 3 study of enzalutamide in non-metastatic (M0) castration-resistant prostate cancer (CRPC) patients
22. Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study
23. 7114 POSTER DISCUSSION Appropriateness of Treatment Options for the Management of Patients With Advanced Renal Cell Carcinoma (RCC) Using the Validated Semi Quantitative RAND Corporation/University of California, Los Angeles (RAND/UCLA) Methodology
24. 227 ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER: 10-YEAR FOLLOW-UP RESULTS
25. 587 Differential susceptibility to Urethane-induced lung cancer among mouse strains: a redox imbalance issue
26. 7106 Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC)
27. 7119 Genitourinary malignancies – Renal cancer Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial
28. SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY) LOCALISED PROSTATE CANCER GUIDELINES PROPOSALS IN SENIOR ADULT MEN
29. VIA.1 SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men
30. 37 INVITED Novel targeted and signalling pathway inhibitors – ongoing studies
31. 4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients
32. 1305 POSTER SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men
33. POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men
34. 311 PAIN AND PSA RESPONSES IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER TREATED WITH SATRAPLATIN: RESULTS OF THE SPARC PHASE III TRIAL
35. Chemotherapy for local treatment of bladder cancer
36. Promises and Challenges of Oncology and Hematology, Including Geriatric Oncology
37. 857 Phase II study of low dose thalidomide and interferon-alpha in metastatic renal cell carcinoma (RCC)
38. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
39. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why
40. Gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma
41. A critical review of the management of bladder cancer
42. Book review
43. 1142 Neo-adjuvant M-VAC chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma (TCC) of the bladder
44. Phase II studies of docetaxel in the treatment of various solid tumours
45. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives
46. Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.